John Cooper Cox

USPTO Granted Patents = 10 (Patent Applications = 1)

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 3 (Patent Applications = 1)

Average Co-Inventor Count = 3.1

ph-index = 6

Forward Citations = 145(Granted Patents)

Location History:

Bullengarook, AU (1999 - 2012)
Victoria, AU (2004 - 2013)

Company Filing History:

The University of Queensland

patents

4. 3 out of 832,891

Other

patents

where one patent can have more than one assignee

Years Active: 1999-2013

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8466265 - Therapeutic antibody purification method and method of use (2013-06-18),

2. 8173141 - Immunogenic complexes and methods relating thereto (2012-05-08),

3. 7776343 - Immunogenic complexes and methods relating thereto (2010-08-17),

4. 6814981 - Ganglioside immunostimulating complexes and uses thereof (2004-11-09),

5. 6726912 - Papillomavirus polyprotein constructs (2004-04-27),

6. 6365160 - Papillomavirus polyprotein constructs (2002-04-02),

7. 6352697 - Saponin preparations and use thereof in iscoms (2002-03-05),

8. 6306397 - Variants of human papilloma virus antigens (2001-10-23),

9. 6004557 - Variants of human papillomavirus antigens (1999-12-21),

10. 5902565 - Spray dried vaccine preparation comprising aluminium adsorbed immunogens (1999-05-11),

Title: The Innovative Contributions of John Cooper Cox

Introduction

John Cooper Cox, an accomplished inventor based in Bullengarook, Australia, is known for his significant contributions to the field of therapeutic antibodies. With a remarkable portfolio of 10 patents, Cox stands out as a pioneer in developing methods that advance healthcare solutions, particularly in the realm of neurodegenerative diseases.

Latest Patents

Cox's latest patents are testament to his innovative spirit and commitment to medical research. One of his notable inventions is a "Therapeutic antibody purification method and method of use," which details a groundbreaking approach to preparing anti-beta amyloid immunoglobulin. This method involves treating human plasma antibodies under specific alkaline conditions, allowing for the dissociation of beta amyloid proteins. The resulting product is substantially free of beta amyloid protein and holds therapeutic potential against conditions like Alzheimer’s disease.

Another significant patent from Cox is titled "Immunogenic complexes and methods relating thereto." This invention encompasses an immunogenic complex that combines a charged organic carrier with a charged antigen. The design of these complexes is aimed at enhancing the body's cytotoxic T-lymphocyte response, thus proving essential as therapeutic and prophylactic agents in immunology.

Career Highlights

Throughout his career, John Cooper Cox has made strides in research, working with prominent companies such as CSL Limited. His contributions to the field have been recognized for their innovative approaches and potential applications in medical treatment.

Collaborations

Cox has collaborated with notable professionals in the industry, including Stirling John Edwards and Elizabeth Ann Webb. These collaborations have enabled the exchange of valuable ideas and advancements in immunological research, furthering the progress in the field.

Conclusion

John Cooper Cox represents a significant force in the realm of medical innovations. His extensive patent portfolio and collaborative efforts reflect his dedication to improving therapeutic approaches for diseases associated with beta amyloid plaques. As he continues to push the boundaries of scientific research, Cox's work is bound to leave a lasting impact on healthcare solutions and therapeutic advancements.

This text is generated by artificial intelligence and may not be accurate.